Cerebrospinal fluid/serum IgG index is correlated with medial temporal lobe atrophy in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 2, 2008, Pages 144-147

  Matsumoto, Yasuko ^a   Yanase, Daisuke ^a   Noguchi Shinohara, Moeko ^a   Ono, Kenjiro ^a   Yoshita, Mitsuhiro ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; IgG index; Medial temporal lobe atrophy; MRI, inflammation

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN G;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CORRELATION ANALYSIS; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATROPHY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SPONDYLITIS; TEMPORAL LOBE;

EID: 38849140874     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112555     Document Type: Article

References (32)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al: Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
2. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al: In vivo measurement of activated microglia in dementia. Lancet 2001;358:766.
3. Tarkoweski E, Andreasen N, Tarkowski A, Blennow K: Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1200-1205.
4. Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al: Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography: a pilot study. Eur Neurol 2003;50:39-47.
5. Rosenberg PB: Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry 2005;17:503-514.
6. Czirr E, Weggen S: Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neurodegener Dis 2006;3:298-304.
7. Hirohata M, Ono K, Naiki H, Yamada M: Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005;49:1088-1099.
8. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28:639-647.
9. McGeer PL, Rogers J, McGeer EG: Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006;9:271-276.
10. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12:1005-1015.
11. Czirr E, Weggen S: Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neurodegener Dis 2006;3:298-304.
12. Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F: Neuronal damage in brain inflammation. Arch Neurol 2007;64:185-189.
13. Aisen PS: The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002;1:279-284.
14. Launer L: Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drug 2003;63:731-739.
15. Kay AD, May C, Papadopoulos NM, Costello B, Atack JR, Luxenberg JS, et al: CSF and serum concentrations of albumin and IgG in Alzheimer's disease. Neurobiol Aging 1987;8:21-25.
16. Leonardi A, Gandolfo C, Caponnetto C, Arata L, Vecchia R: The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci 1985;67:253-261.
17. Elovaara I, Palo J, Erkinjuntti T, Sulkava R: Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia. Eur Neurol 1987;26:229-234.
18. Blennow K, Wallin A, Davidsson P, Fredman P, Gottfries CG, Svennerholm L: Intrablood-brain barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1990;4:79-86.
19. Frolich L, Kornhuber J, Ihl R, Fritze J, Maurer K, Riederer P: Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur Arch Psychiatry Clin Neurosci 1991;240:363-366.
20. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M: Bloodbrain permeability correlates with medial temporal lobe atrophy but not with amyloid-β protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:241-245.
21. McKhann G, Drachman D, Folstein M, Katzman M, Price D, Atadlan E: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
22. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al: A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
23. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972.
24. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA: Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995;242:557-560.
25. Tibbling G: Principles of albumin and IgG analyses in neurological disorder. I. Establishment of reference value. Scand J Clin Lab Invest 1977;37:385-390.
26. Kataoka S, Paidi M, Howard BV: Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem 1994;40:11-13.
27. Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, et al: Amyloid beta plaque-associated proteins C1q and SAP enhance the Aβ1-41 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 2003;105:135-144.
28. Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, et al: Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 2004;25:861-871.
29. Martinez M, Fernandez VE, Frank A, De la Fuente M, Hernanz A: Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentration. Brain Res 2000;869:216-219.
30. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S: Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:136-144.
31. Roe CM, Xiong C, Miller JP, Morris JC: Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 2007;68:223-228.
32. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321-322.